Table 1 Patient characteristics, bivariate analysis for biopsy, and overall mortality
From: Biopsy of breast cancer metastases: patient characteristics and survival
Variable | No. Patients | No Biopsy | Biopsy | All Cause Mortality | |||||
|---|---|---|---|---|---|---|---|---|---|
No. (%) | No. (%) | P value | OR (95% CI) | % total | P value | HR (95% CI) | |||
Factors in initial diagnosis | |||||||||
Year of initial diagnosis | Total | 409 | 244 (60) | 165 (40) | 80.9 | ||||
1980–99 | 134 | 76 (57) | 58 (43) | Ref | 1.00 | 85.1 | Ref. | 1.00 | |
2000–09 | 256 | 154 (60) | 102 (40) | 0.512 | 0.87 (0.57–1.33) | 79.7 | 0.000 | 1.54 (1.22–1.94) | |
2010–14 | 19 | 14 (74) | 5 (26) | 0.167 | 0.47 (0.16–1.37) | 68.4 | 0.000 | 5.35 (2.95–9.70) | |
Stage at initial diagnosis | Stage 0-IIA | 172 | 82 (48) | 90 (52) | Ref | 1.00 | 73.8 | Ref. | 1.00 |
Stage IIB-III | 232 | 161 (69) | 71 (31) | 0.000 | 0.40 (0.27–0.61) | 87.1 | 0.001 | 1.46 (1.17–1.82) | |
Missing | 5 | 1 (20) | 4 (80) | 40.0 | |||||
Grade at initial diagnosis | 1.0 | 16 | 5 (31) | 11 (69) | Ref | 1.00 | 62.5 | Ref. | 1.00 |
2.0 | 169 | 103 (61) | 66 (39) | 0.028 | 0.29 (0.10–0.88) | 80.5 | 0.167 | 1.57 (0.83–3.00) | |
3.0 | 146 | 90 (62) | 56 (38) | 0.026 | 0.28 (0.09–0.86) | 85.6 | 0.009 | 2.37 (1.24–4.52) | |
Missing | 78 | 46 (59) | 32 (41) | 76.9 | |||||
HR and HER2 at initial diagnosis | HR+/HER2+ | 48 | 38 (79) | 10 (21) | Ref. | 1.00 | 75.0 | Ref. | 1.00 |
HR-/HER2- | 49 | 35 (71) | 14 (29) | 0.379 | 1.52 (0.60–3.86) | 87.8 | 0.004 | 1.92 (1.24–3.00) | |
HR-/HER2+ | 44 | 35 (80) | 9 (20) | 0.964 | 0.98 (0.36–2.69) | 86.4 | 0.032 | 1.65 (1.04–2.61) | |
HR+/HER2- | 173 | 99 (57) | 74 (43) | 0.007 | 2.84 (1.33–6.07) | 80.3 | 0.090 | 1.38 (0.95–1.99) | |
Missing HR or HER2 | 95 | 37 (39) | 58 (61) | 0.000 | 5.96 (2.65–13.38) | 78.9 | 0.429 | 1.17 (0.79–1.75) | |
Factors in metastatic recurrence | |||||||||
Time to recurrence | <3 years | 145 | 120 (83) | 25 (17) | Ref | 1.00 | 93.1 | Ref | 1.00 |
> = 3 years | 264 | 124 (47) | 140 (53) | 0.000 | 5.42 (3.31–8.88) | 74.2 | 0.000 | 0.58 (0.47–0.73) | |
Age at recurrence | <70 years | 348 | 207 (59) | 141 (41) | Ref | 1.00 | 80.7 | Ref | 1.00 |
> = 70 years | 61 | 37 (60) | 24 (40) | 0.863 | 0.95 (0.55–1.66) | 82.0 | 0.004 | 1.57 (1.16–2.12) | |
Years of metastatic recurrence | 2000–04 | 116 | 93 (80) | 23 (20) | Ref | 1.00 | 96.6 | Ref. | 1.00 |
2005–09 | 165 | 103 (62) | 62 (38) | 0.002 | 2.43 (1.40–4.24) | 90.3 | 0.433 | 1.10 (0.86–1.41) | |
2010–14 | 128 | 48 (37) | 80 (63) | 0.000 | 6.74 (3.77–12.04) | 54.7 | 0.596 | 1.09 (0.80–1.48) | |
No of metastatic sites at recurrence | Single site | 123 | 83 (64) | 40 (36) | Ref | 1.00 | 78.9 | Ref | 1.00 |
2–3 sites | 136 | 76 (56) | 60 (44) | 0.056 | 1.64 (0.99–2.72) | 80.1 | 0.011 | 1.43 (1.09–1.89) | |
>3 sites | 150 | 85 (57) | 65 (43) | 0.068 | 1.59 (0.97–2.61) | 83.3 | 0.001 | 1.57 (1.20–2.06) | |
Brain metastases | No | 376 | 219 (58) | 157 (42) | Ref | 1.00 | 79.8 | Ref. | 1.00 |
Yes | 33 | 25 (76) | 8 (24) | 0.054 | 0.45 (0.20–1.02) | 93.9 | 0.000 | 2.60 (1.79–3.79) | |
Liver metastases | No | 289 | 176 (61) | 113 (39) | Ref | 1.00 | 78.5 | Ref. | 1.00 |
Yes | 120 | 68 (57) | 52 (43) | 0.427 | 1.19 (0.77–1.83) | 86.7 | 0.007 | 1.38 (1.09–1.74) | |
Lung metastases | No | 253 | 150 (59) | 103 (41) | Ref | 1.00 | 79.4 | Ref. | 1.00 |
Yes | 156 | 90 (60) | 62 (40) | 0.846 | 0.96 (0.64–1.44) | 83.3 | 0.015 | 1.32 (1.05–1.64) | |
HR and HER2 at recurrence | HR+/HER2+ | 26 | 69.2 | Ref | 1.00 | ||||
HR-/HER2- | 34 | 85.3 | 0.008 | 2.23 (1.24–4.02) | |||||
HR-/HER2+ | 15 | 53.3 | 0.295 | 1.56 (0.68–3.61) | |||||
HR+/HER2- | 90 | 60.0 | 0.665 | 1.13 (0.66–1.92) | |||||
Missing | 244 | 91.0 | 0.004 | 2.01 (1.24–3.26) | |||||
Site of metastasis at recurrence | No brain, liver or lung | 158 | 89 (56) | 69 (44) | Ref | 1.00 | 75.3 | Ref. | 1.00 |
Liver or lung | 183 | 113 (62) | 70 (38) | 0.310 | 0.80 (0.52–1.23) | 81.4 | 0.020 | 1.33 (1.05–1.70) | |
Liver & lung | 35 | 17 (49) | 18 (51) | 0.405 | 1.37 (0.66–2.84) | 91.4 | 0.000 | 2.25 (1.52–3.33) | |
Brain | 33 | 25 (76) | 8 (24) | 0.043 | 0.41 (0.18–0.97) | 93.9 | 0.000 | 3.22 (2.15–4.81) | |
LAD at recurrence | No LAD | 239 | 169 (71) | 70 (29) | Ref | 1.00 | 83.7 | Ref. | 1.00 |
LAD | 170 | 75 (44) | 95 (56) | 0.000 | 3.06 (2.03–4.61) | 77.1 | 0.933 | 0.99 (0.79–1.24) | |
Biopsy Status | No | 244 | 91.0 | Ref | 1.00 | ||||
Yes | 165 | 66.1 | 0.000 | 0.64 (0.51–0.81) | |||||